Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison

Blood (2022) 140 (20): 2142–2145.

https://doi.org/10.1182/blood.2022016953

Published: 2022

Includes: Supplemental data

Journal Articles

Hypertension and incident cardiovascular events following ibrutinib initiation

Tyler Dickerson, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Kyle Porter, Devin Haddad, Avirup Guha, Kerry A. Rogers, Seema Bhat, John C. Byrd, Jennifer A. Woyach, Farrukh Awan, Daniel Addison

Blood (2019) 134 (22): 1919–1928.

https://doi.org/10.1182/blood.2019000840

Published: 2019

Includes: Supplemental data

Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2015) 126 (23): 318.

https://doi.org/10.1182/blood.V126.23.318.318

Published: 2015

Journal Articles

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Farrukh Awan, MD MS, Jeffrey A. Jones, MD MPH, Sharon Waymer, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2953.

https://doi.org/10.1182/blood.V126.23.2953.2953

Published: 2015

Journal Articles

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Ta-Ming Liu, Yonghua Ling, Jennifer A. Woyach, Kyle Beckwith, Yuh-Ying Yeh, Erin Hertlein, Xiaoli Zhang, Amy Lehman, Farrukh Awan, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Jessica MacMurray, Santosh B. Salunke, Ching-Shih Chen, Mitch A. Phelps, John C. Byrd, Amy J. Johnson

Blood (2015) 125 (2): 284–295.

https://doi.org/10.1182/blood-2014-06-583518

Published: 2015

Includes: Supplemental data

Journal Articles

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Jason Gotlib, MD MS, Hanneke C. Kluin-Nelemans, MD PhD, Tracy I. George, MD, Cem Akin, MD PhD, Karl Sotlar, MD, Olivier Hermine, MD PhD, Farrukh Awan, MD MS, Elizabeth O Hexner, MD, Michael Mauro, MD, David Sternberg, MD PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Eric Stanek, PharmD, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2014) 124 (21): 636.

https://doi.org/10.1182/blood.V124.21.636.636

Published: 2014

Journal Articles

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Jennifer A. Woyach, MD, Farrukh Awan, MD MS, Ian Flinn, Jesus G. Berdeja, MD, Elizabeth A Wiley, Sharmeen Mansoor, Ying Huang, MA, MS, Gerard Lozanski, MD, Paul A. Foster, MD, John C. Byrd, MD

Blood (2014) 124 (21): 1993.

https://doi.org/10.1182/blood.V124.21.1993.1993

Published: 2014

Journal Articles

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

Kerry A. Rogers, MD, Jennifer A. Woyach, MD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Kristie A. Blum, MD, Joseph M Flynn, DO, MPH, Samantha Jaglowski, MD MPH, Gerard Lozanski, MD, Kami J. Maddocks, MD, John C. Byrd, MD, Jeffrey A. Jones, MD

Blood (2014) 124 (21): 1997.

https://doi.org/10.1182/blood.V124.21.1997.1997

Published: 2014

Journal Articles

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Kami J. Maddocks, MD, John Pagel, MD PhD, John C. Byrd, MD, Scott Stromatt, Farrukh Awan, MD MS

Blood (2014) 124 (21): 4671.

https://doi.org/10.1182/blood.V124.21.4671.4671

Published: 2014

Journal Articles

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Tadeusz Robak, MD, Andrzej Hellman, Javier Loscertales, MD, Ewa Lech-Maranda, MD PhD, John M. Pagel, MD PhD, Anthony R. Mato, MD, John C. Byrd, MD, Farrukh Awan, MD MS, Holger Hebart, MD, Jose A Garcia-Marco, MD PhD, Brian T. Hill, MD PhD, Michael Hallek, MD, Scott Stromatt, Janusz Kloczko, Professor

Blood (2014) 124 (21): 5642.

https://doi.org/10.1182/blood.V124.21.5642.5642

Published: 2014

Journal Articles

Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients

Jiazhu Wu, B. S., Xiaojing Xu, PhD, Lirong Pei, B.S., Eun-Joon Lee, PhD, Austin Shull, B.S., Farrukh Awan, MD MS, Xiaoling Wang, PhD, Lei Fan, MD, PhD, Li Jianyong, MD PhD, Xu Wei, MD PhD, Huidong Shi, PhD

Blood (2014) 124 (21): 3552.

https://doi.org/10.1182/blood.V124.21.3552.3552

Published: 2014

Journal Articles

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

Jeffrey Alan Jones, MD MPH, Susan Geyer, PhD, Leslie A. Andritsos, MD, Farrukh Awan, MD MS, Joseph M Flynn, DO, MPH, Kami J. Maddocks, MD, Anissa Bingman, M.S., Amy J. Johnson, PhD, Nyla A. Heerema, PhD, Cathy Brookfield, RN, John C. Byrd, MD, Michael R. Grever, MD

Blood (2014) 124 (21): 329.

https://doi.org/10.1182/blood.V124.21.329.329

Published: 2014

Journal Articles

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

Jennifer A. Woyach, Farrukh Awan, Ian W. Flinn, Jesus G. Berdeja, Elizabeth Wiley, Sharmeen Mansoor, Ying Huang, Gerard Lozanski, Paul A. Foster, John C. Byrd

Blood (2014) 124 (24): 3553–3560.

https://doi.org/10.1182/blood-2014-08-593269

Published: 2014

Includes: Supplemental data

Journal Articles

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US

Anand P. Jillella, MD, Ravindra B. Kolhe, MD, PhD, Farrukh Awan, MD, MS, Kavita Natrajan, MBBS, Vamsi Kota, M.B;B.S

Blood (2013) 122 (21): 5597.

https://doi.org/10.1182/blood.V122.21.5597.5597

Published: 2013

Journal Articles

Congestive Heart Failure (CHF) During Induction In ACUTE Promyelocytic Leukemia (APL) Patients

Arati Rani Chand, MBBS, Josh Simmons, MD, Farrukh Awan, MD, MS, Anand P. Jillella, MD, Ravindra B. Kolhe, MD, PhD, Vamsi Kota, M.B;B.S

Blood (2013) 122 (21): 3898.

https://doi.org/10.1182/blood.V122.21.3898.3898

Published: 2013

Journal Articles

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Jason Gotlib, MD, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, John Coombs, PharmD, MBA, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2013) 122 (21): 106.

https://doi.org/10.1182/blood.V122.21.106.106

Published: 2013

Journal Articles

Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients

Jennifer R. Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Coumaran Egile, PhD, Rodrigo Ruiz-Soto, MD, MSc, Farrukh Awan, MD, MS

Blood (2013) 122 (21): 4170.

https://doi.org/10.1182/blood.V122.21.4170.4170

Published: 2013

Journal Articles

DNA Hypomethylation Leads to Aberrant Expression of PD-1 in Chronic Lymphocytic Leukemia

Eun Joon Lee, Ph.D., Jimei Liu, Ph.D., Ethan Speir, James Wilson, B.S., Hena Joshi, B.S., Lirong Pei, B.S., Junfeng Luo, Ph.D., Farrukh Awan, M.D., M.S., David Munn, M.D., Xiao-Jie Yan, M.D., Ph.D., Nicholas Chiorazzi, MD, Huidong Shi, Ph.D.

Blood (2012) 120 (21): 3504.

https://doi.org/10.1182/blood.V120.21.3504.3504

Published: 2012

Journal Articles

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Jason Gotlib, MD, MS, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, MD, PhD, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael J. Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2012) 120 (21): 799.

https://doi.org/10.1182/blood.V120.21.799.799

Published: 2012

Journal Articles

A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)

Anand P. Jillella, MD, Farrukh Awan, MD, MS, Ravindra B. Kolhe, MD, PhD, Jeremy M Pantin, MB.BS., Devi D Morrison, Vamsi Kota, MBBS

Blood (2012) 120 (21): 4317.

https://doi.org/10.1182/blood.V120.21.4317.4317

Published: 2012

NARROW

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Hypertension and incident cardiovascular events following ibrutinib initiation

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Genome-Wide DNA Methylation Analysis Identifies Aberrant Epigenetic Changes in CD8+ T Cells from Chronic Lymphocytic Leukemia Patients

Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US

Congestive Heart Failure (CHF) During Induction In ACUTE Promyelocytic Leukemia (APL) Patients

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients

DNA Hypomethylation Leads to Aberrant Expression of PD-1 in Chronic Lymphocytic Leukemia

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only